Article
Serum metabolic signatures are associated with anti-drug antibody development in rheumatoid arthritis patients treated with adalimumab
2025-08-26
Abstract excerpt
<h4>Objectives</h4> Development of anti-drug antibodies (ADAs) is a barrier to long-term efficacy of biologic therapies in rheumatoid arthritis (RA), but no biomarkers exist to predict ADA formation. This study explored the potential of serum metabolomics to predict development of ADAs to adalimumab in patients with RA. <h4>Methods</h4> Serum from patients with RA (n=47), treatment naïve for tumour necrosis fact...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 629897b5-ce08-5241-b48d-48a08f0ff4fe
- DOI
- 10.1101/2025.08.22.25334214
